Identifying treatment weaknesses in acute myeloid leukemia (AML) through studying a specific gene's role.
Uncovering therapeutic vulnerabilities in AML through mechanistic interrogation of MECOM activity
This study is looking at a protein called MECOM to understand how it affects acute myeloid leukemia (AML) and hopes to find new ways to treat patients by discovering important genes that help keep the leukemia going.
Quick facts
| Grant type | Career grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Ut Southwestern Medical Center NIH-funded |
| Lab location | 1 site (Dallas, United States) |
| Project ID | NIH-11248254 on NIH RePORTER |
What this research studies
This research investigates the role of the MECOM transcription factor in acute myeloid leukemia (AML) to uncover new treatment strategies. By examining how MECOM regulates gene expression and interacts with other cellular pathways, the study aims to identify critical genes that contribute to the maintenance of AML. The approach involves detailed mechanistic studies to pinpoint essential co-regulators and downstream effectors of MECOM, which could lead to targeted therapies for patients with AML.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with acute myeloid leukemia who may benefit from novel therapeutic strategies.
Not a fit: Patients with other types of leukemia or those who do not have AML may not receive any benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new targeted therapies that improve treatment outcomes for patients with AML.
How similar studies have performed: Other research has shown promise in targeting specific gene pathways in leukemia, suggesting that this approach could yield valuable insights.
Where this research is happening
Dallas, United States
- Ut Southwestern Medical Center — Dallas, United States (Active)
Researchers
- Principal investigator: Voit, Richard a — Ut Southwestern Medical Center
- Study coordinator: Voit, Richard a
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.